Artificial Intelligence Designs Anti-Cancer Molecules to Target CDK9
Artificial Intelligence Designs Anti-Cancer Molecules to Target CDK9
Publish Date: 2026-01-12 17:40:00
Source Domain: www.newswise.com
- Researchers from the Sbarro Institute, the National Cancer Institute – Pascale Foundation, and the University of Pisa collaborated to leverage artificial intelligence (AI) for the design of new antitumor molecules.
- The study focused on identifying molecules capable of inhibiting the enzymatic activity of the CDK9 protein, which is highly associated with uncontrolled tumor cell growth.
- Machine learning algorithms were used for a large-scale virtual screening to select 14 candidate molecules that were then tested in cellular models of cervical carcinoma and breast cancer.
- Two compounds were identified that exhibited significant cytotoxic activity and reduced tumor cell viability, demonstrating promising therapeutic potential.
- The study highlights the effectiveness of AI in rapidly identifying promising drug candidates, reducing time and costs in the drug discovery phase.
- The integration of AI technology with human expertise promises to accelerate the development of targeted and effective cancer therapies.
- The Sbarro Health Research Organization, based in Philadelphia and affiliated with Temple University, is at the forefront of groundbreaking research in cancer, diabetes, and cardiovascular disease.
